Concise Review: Quantitative Detection and Modeling the In Vivo Kinetics of Therapeutic Mesenchymal Stem/Stromal Cells.
Concise Review: Quantitative Detection and Modeling the In Vivo Kinetics of Therapeutic Mesenchymal Stem/Stromal Cells.
复制标题
DOI：
10.1002/sctm.17-0209
复制
发表时间：
2018-01
影响因子：
6
通讯作者：
Wang H
中科院分区：
文献类型：
--
作者：
Brooks A;Futrega K;Liang X;Hu X;Liu X;Crawford DHG;Doran MR;Roberts MS;Wang H
间充质干细胞(MSCs)是一种基于细胞的治疗多种疾病的有前景的工具。目前，临床研究中治疗方案的优化由于细胞剂量的变化、输送MSCs的不同方法以及用于体内追踪MSCs的方法的多样性而变得复杂。大多数研究采用剂量递增的方法，并试图将疗效与细胞总剂量相关联。通过具体了解MSC在体内的分布、长期生存能力以及它们的生物学命运，可以加速优化。虽然在临床试验中不可能在全身给药后很长一段时间内定量检测到大多数靶器官中的MSCs，但越来越有可能应用药代动力学模型来预测它们的分布和持久性。这篇综述概述了目前对外源性MSCs体内动力学的理解，对这些研究中用于定量MSC检测的方法进行了重要的分析，并讨论了药代动力学模型在这些数据中的应用。最后，我们对使用药代动力学模型来最大化MSC治疗和最小化潜在副作用的有效治疗策略的未来发展提供了见解和展望。干细胞转化医学2018；7：78-86
Mesenchymal stem/stromal cells (MSCs) present a promising tool in cell‐based therapy for treatment of various diseases. Currently, optimization of treatment protocols in clinical studies is complicated by the variations in cell dosing, diverse methods used to deliver MSCs, and the variety of methods used for tracking MSCs in vivo. Most studies use a dose escalation approach, and attempt to correlate efficacy with total cell dose. Optimization could be accelerated through specific understanding of MSC distribution in vivo, long‐term viability, as well as their biological fate. While it is not possible to quantitatively detect MSCs in most targeted organs over long time periods after systemic administration in clinical trials, it is increasingly possible to apply pharmacokinetic modeling to predict their distribution and persistence. This Review outlines current understanding of the in vivo kinetics of exogenously administered MSCs, provides a critical analysis of the methods used for quantitative MSC detection in these studies, and discusses the application of pharmacokinetic modeling to these data. Finally, we provide insights on and perspectives for future development of effective therapeutic strategies using pharmacokinetic modeling to maximize MSC therapy and minimize potential side effects. Stem Cells Translational Medicine 2018;7:78–86
登录
查看更多内容
影响因子：
7.5
作者：
Kol A;Wood JA;Carrade Holt DD;Gillette JA;Bohannon-Worsley LK;Puchalski SM;Walker NJ;Clark KC;Watson JL;Borjesson DL
通讯作者：
Borjesson DL
影响因子：
37.8
作者：
Hofmann, M;Wollert, KC;Drexler, H
通讯作者：
Drexler, H
影响因子：
5.3
作者：
Barbosa da Fonseca, Lea Mirian;Gutfilen, Bianca;de Freitas, Gabriel R.
通讯作者：
de Freitas, Gabriel R.
影响因子：
20.3
作者：
Dominici, Massimo;Marino, Roberta;Horwitz, Edwin M.
通讯作者：
Horwitz, Edwin M.
影响因子：
13.6
作者：
Kunter, Uta;Rong, Song;Floege, Juergen
通讯作者：
Floege, Juergen